Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025. The company recorded a net loss of $23.0 million, translating to $0.31 per basic and diluted share. This loss includes non-cash charges totaling $3.4 million, primarily from share-based compensation and depreciation expenses. Research and development expenses for the quarter stood at $20.8 million, with non-cash stock-based compensation accounting for $0.9 million of this amount. General and administrative expenses were $6.4 million, including $1.2 million in non-cash stock-based compensation. Nkarta ended the quarter with $334.0 million in cash, cash equivalents, restricted cash, and investments in marketable securities. The company anticipates that this cash position will be sufficient to fund its operations into 2029. Significant corporate updates include the appointment of Shawn Rose, M.D. Ph.D., as Chief Medical Officer and Head of Research and Development. Dr. Rose brings extensive experience from previous roles with Johnson & Johnson and BMS, having developed multiple pioneering medicines for autoimmune conditions. Additionally, Nkarta's NKX019 clinical programs in autoimmune diseases are continuing to enroll patients, with preliminary data from the Ntrust-1 and Ntrust-2 clinical trials expected in the second half of 2025.